文献速递神经肌肉病

血浆神经丝轻链与神经肌肉转诊队列诊断分类的关联:横断面研究

Association of Plasma Neurofilament Light Chain With Diagnostic Classification in a Neuromuscular Referral Cohort: A Cross-Sectional Study.
PubMed 文献 · Neurology · 2026-07-13

梅奥诊所2022年4月至2024年4月对306例神经肌肉专科就诊患者进行横断面研究,评估年龄校正后异常血浆神经丝轻链(pNfL)与诊断分类的关联。结果显示异常pNfL与运动神经元病(RRR 18.47)和活动性神经病(RRR 7.30)分类可能性增高相关,鉴别活动性与非活动性神经病的AUC为0.79,运动神经元病与其他诊断鉴别的AUC为0.85。

要点

  • 年龄校正后异常pNfL与运动神经元病和活动性神经病分类可能性增高独立相关。
  • pNfL鉴别活动性与非活动性神经病具有中等诊断准确性(AUC 0.79)。
  • pNfL鉴别运动神经元病与其他诊断具有良好诊断准确性(AUC 0.85)。

核心结论

  • 在神经肌肉转诊队列中,年龄校正后异常pNfL浓度在临床活动性轴索损伤的诊断分类中更常见。
  • pNfL可能作为神经肌肉诊断评估的辅助工具。

研究设计与样本

  • 横断面研究,纳入2022年4月至2024年4月在梅奥诊所(罗切斯特)神经肌肉专科就诊并常规检测pNfL的患者306例。
  • 诊断由共识审查分配至预设类别:运动神经元病、活动性神经病、非活动性神经病和结构性病因。

主要发现

  • 中位pNfL浓度在各诊断组间存在差异(p < 0.0001),运动神经元病和活动性神经病中最高。
  • 校正神经病损伤评分和症状持续时间后,异常pNfL与运动神经元病分类可能性增高相关(RRR 18.47,95% CI 8.77-38.86)。
  • 异常pNfL与活动性神经病分类可能性增高相关(RRR 7.30,95% CI 2.50-21.34),与结构性病因无关联。
  • 鉴别活动性与非活动性神经病的AUC为0.79(95% CI 0.70-0.88),鉴别运动神经元病与其他诊断的AUC为0.85(95% CI 0.80-0.90)。

关键数值与推荐

  • 异常pNfL定义为年龄校正后第97.5百分位参考限以上。
  • 活动性神经病由预设的诊断特异性操作标准定义,纳入治疗状态、临床复发或进展、症状出现时间和炎症病理证据。

临床怎么用

  • 在神经肌肉专科评估中,pNfL可作为辅助工具帮助区分活动性轴索损伤相关疾病与非活动性神经病或结构性病因。

局限性

  • 横断面设计限制因果推断。
  • 便利抽样可能影响样本代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Plasma neurofilament light chain (pNfL) is a blood-based biomarker of axonal injury elevated in several neuromuscular disorders. While previous studies have compared individual diseases with healthy controls, less is known about how pNfL performs across clinically relevant neuromuscular presentations encountered in subspecialty practice, particularly in distinguishing active from inactive neuropathies. We evaluated whether abnormal age-adjusted pNfL concentrations are associated with clinically relevant diagnostic categories and whether pNfL discriminates between active and inactive neuropathies. METHODS: We conducted a cross-sectional study of patients evaluated by neuromuscular specialists at Mayo Clinic (Rochester, MN) between April 2022 and April 2024, in whom pNfL was ordered as part of routine clinical care. Diagnoses were assigned to prespecified categories by consensus review, including motor neuron disease (MND), active neuropathy, inactive neuropathy, and structural etiologies. Clinically active neuropathy was defined using prespecified, diagnosis-specific operational criteria incorporating treatment status, clinical relapse or progression, time from symptom onset, and pathologic evidence of inflammation. Abnormal pNfL was defined using previously established age-adjusted 97.5th percentile reference limits. Multinomial logistic regression evaluated associations between abnormal pNfL and diagnostic category, adjusting for neuropathy impairment score and symptom duration. Receiver operating characteristic (ROC) analyses assessed discrimination between prespecified groups. RESULTS: Among 306 patients (mean age 62.2 years, 41.5% female), 179 (58.5%) had MND, 28 (9.1%) active neuropathy, 75 (12.1%) inactive neuropathy, and 24 (7.8%) structural etiologies. Median pNfL concentrations differed across diagnostic groups (p < 0.0001) and were highest in MND and active neuropathy. After adjustment, abnormal pNfL was associated with a higher relative likelihood of classification as MND (relative risk ratio [RRR] 18.47, 95% CI 8.77-38.86) and active neuropathy (RRR 7.30, 95% CI 2.50-21.34) compared with inactive neuropathies. No association was observed with structural etiologies. Discrimination between active and inactive neuropathy was moderate (area under the curve [AUC] 0.79, 95% CI 0.70-0.88), and discrimination for MND vs all other diagnoses was good (AUC 0.85, 95% CI 0.80-0.90). DISCUSSION: In this cross-sectional cohort, abnormal age-adjusted pNfL concentrations were more frequently observed in diagnostic categories characterized by clinically active axonal injury than in inactive neuropathies and structural conditions. These findings suggest a potential role for pNfL as an adjunctive tool in neuromuscular diagnostic evaluation. Interpretation is limited by the cross-sectional design and convenience sampling. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that abnormal age-adjusted pNfL distinguishes active neuropathies from inactive neuropathies with moderate diagnostic accuracy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schipani ES, Jones FJS, Staff NP, et al. Association of Plasma Neurofilament Light Chain With Diagnostic Classification in a Neuromuscular Referral Cohort: A Cross-Sectional Study. Neurology. 2026. PMID: 42441926. doi:10.1212/WNL.0000000000218304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。